Evoke Pharma (EVOK) vs. Innoviva (INVA) Head-To-Head Comparison

Evoke Pharma (NASDAQ: EVOK) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Valuation and Earnings

This table compares Evoke Pharma and Innoviva’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Evoke Pharma N/A N/A N/A ($0.97) -3.02
Innoviva $175.98 million 7.43 $142.91 million $0.87 13.74

Innoviva has higher revenue and earnings than Evoke Pharma. Evoke Pharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Evoke Pharma has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Evoke Pharma and Innoviva, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evoke Pharma 0 1 6 0 2.86
Innoviva 1 2 1 0 2.00

Evoke Pharma currently has a consensus price target of $8.86, indicating a potential upside of 202.29%. Innoviva has a consensus price target of $13.00, indicating a potential upside of 8.79%. Given Evoke Pharma’s stronger consensus rating and higher possible upside, equities analysts clearly believe Evoke Pharma is more favorable than Innoviva.

Profitability

This table compares Evoke Pharma and Innoviva’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evoke Pharma N/A -167.16% -80.56%
Innoviva 52.91% -33.55% 26.40%

Insider & Institutional Ownership

12.9% of Evoke Pharma shares are owned by institutional investors. Comparatively, 69.7% of Innoviva shares are owned by institutional investors. 20.0% of Evoke Pharma shares are owned by company insiders. Comparatively, 1.6% of Innoviva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Innoviva beats Evoke Pharma on 7 of the 11 factors compared between the two stocks.

Evoke Pharma Company Profile

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Innoviva Company Profile

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

What are top analysts saying about Evoke Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Evoke Pharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit